The Indianapolis-based drugmaker is working with financial advisers to gauge buyer interest in a portfolio of older, off-patent drugs. The portfolio is valued around $200 million to $300 million.
Potential buyers may include other pharmaceutical companies with a presence in Asia.
Following in the steps of other drugmakers, Eli Lilly has been trimming its portfolio of older drugs in an effort to refocus on more profitable areas, such as oncology.
Read the full report here.
More articles on pharmacy:
Florida adds CVS, Walgreens to opioid lawsuit
Pfizer to hike price of 41 drugs in January
Bristol-Myers Squibb to lay off 69 employees in Florida
